Open Nav

Please submit your session questions in advance at

Michael Tymianski


NoNO Inc.

Dr. Michael Tymianski is the founder, president and CEO of NoNO Inc. He is also the former Chief of Neurosurgery at the University Health Network, Canada’s largest research hospital, a Canada Research Chair (Tier 1) in Translational Stroke Research, and a research scientist. Dr. Tymianski is the inventor of two novel classes of CNS agents. The first are PSD95 inhibitors, which are peptides that uncouple glutamatergic signaling from deleterious cell death pathways. The PSD95 Inhibitor NA-1 has been developed by NoNO and is currently in two phase 3 trials. The second class of agents comprise compounds that inhibit TRPM7, a ubiquitous ion channel, that inhibit tissue ischemia including myocardial ischemia. In 2016 Dr. Tymianski was appointed to the Order of Canada, the cornerstone of the Canadian Honours System, that recognizes outstanding achievement, dedication to the community and service to the nation.

This speaker's sessions:

  • NoNO Inc.
  • Tuesday, February 12
  • 10:45 AM - 11:00 AM